Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

R-Pharm

Status and phase: Completed; Phase 2

Conditions: Breast Cancer; Metastases

Treatments: Drug: Ixabepilone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00080262

CA163-081

Details and patient eligibility

About

The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine (alone or in combination) and be resistant
• No more than 3 prior chemotherapy regimens in the metastatic setting
• Must have at least one target lesion that is radiographically measurable
• Good performance status
• No history of or current brain or leptomeningeal disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

125 participants in 1 patient group

1

Experimental group

Treatment:

Drug: Ixabepilone